MedTrace Logo

Biomarker Study of in Men With PSA Progression on Abi for CR or CS PC (Bio-STAMP)

NCT05705700 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2023-02-27

No results posted yet for this study

Summary

This is a multicenter, Phase II randomized biomarker-based therapeutic study in metastatic prostate cancer experiencing prostate specific antigen (PSA) only progression (without visceral, bone or lymph node progression) while on abiraterone therapy.

Conditions

Interventions

DRUG

Dutasteride

High dose Dutasteride (3.5 mg daily) as add-on therapy at time of PSA progression

DRUG

Abiraterone

1000 mg PO daily

Sponsors & Collaborators

  • Masonic Cancer Center, University of Minnesota

    lead OTHER

Principal Investigators

  • Charles Ryan, MD · Masonic Cancer Center, Univeristy of Minnesota

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-02-28
Primary Completion
2030-01-31
Completion
2030-01-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05705700 on ClinicalTrials.gov